AI Article Synopsis
- Transcatheter mitral valve-in-valve replacement is a less invasive option for high-risk patients with failed bioprosthetic mitral valves, and this study focuses on its outcomes in intermediate-risk patients.
- A total of 50 patients, mostly around 70 years old, were treated using a balloon-expandable valve, and results showed no deaths or strokes within one year post-procedure.
- The procedure led to significant improvement in patients' symptoms and quality of life, with most experiencing low levels of mitral regurgitation and overall better heart function after one year.
Article Abstract
Background: Transcatheter mitral valve-in-valve replacement offers a less-invasive alternative for high-risk patients with bioprosthetic valve failure. Limited experience exists in intermediate-risk patients. We aim to evaluate 1-year outcomes of the PARTNER 3 mitral valve-in-valve study.
Methods: This prospective, single-arm, multicenter study enrolled symptomatic patients with a failing mitral bioprosthesis demonstrating greater than or equal to moderate stenosis and regurgitation and Society of Thoracic Surgeons score ≥3% and <8%. A balloon-expandable transcatheter heart valve (SAPIEN 3, Edwards Lifesciences) was used via a transeptal approach. The primary end point was the composite of all-cause mortality and stroke at 1 year.
Results: A total of 50 patients from 12 sites underwent mitral valve-in-valve from 2018 to 2021. The mean age was 70.1±9.7 years, mean Society of Thoracic Surgeons score was 4.1%±1.6%, and 54% were female. There were no primary end point events (mortality or stroke) through 1 year, and no left-ventricular outflow tract obstruction, endocarditis, or mitral valve reintervention was reported. Six patients (12%) required rehospitalization, including heart failure (n=2), minor procedural side effects (n=2), and valve thrombosis (n=2; both resolved with anticoagulation). An additional valve thrombosis was associated with no significant clinical sequelae. From baseline to 1 year, all subjects with available data had none/trace or mild (grade 1+) mitral regurgitation and the New York Heart Association class improved in 87.2% (41/47) of patients.
Conclusions: Mitral valve-in-valve with a balloon-expandable valve via transseptal approach in intermediate-risk patients was associated with improved symptoms and quality of life, adequate transcatheter valve performance, and no mortality or stroke at 1-year follow-up.
Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03193801.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCINTERVENTIONS.123.013782 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Percutaneous Mitral Valve-in-Ring Procedure in a Case of Severe Mitral Regurgitation Repaired with a Surgical Flexible Ring: A Step-by-Step Description.
Turk Kardiyol Dern Ars
January 2025
Department of Cardiology, Gülhane Faculty of Medicine, University of Health Sciences, Ankara, Türkiye.
Severe mitral regurgitation (MR) following surgical repair of the mitral valve poses a significant clinical challenge. Patients who have undergone surgery are typically at high risk for a second operation. This report details the case of a 54-year-old male who underwent aortic valve replacement and mitral valve repair using a 34-ring, 14 years prior.
View Article and Find Full Text PDFReintervention after aortic root replacement with allograft, xenograft, and stented bioprosthetic valves.
Cardiovasc Revasc Med
December 2024
Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, United States of America; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America. Electronic address:
Background: There has been a significant increase in the utilization of non-mechanical valves in the aortic position over time. However, details in reinterventions after aortic root replacement (ARR) with non-mechanical prosthesis were limited in the literature, despite the potential importance of reinterventions in the lifetime management of aortic valve disease.
Methods: This is a single-center retrospective study, identifying all patients who underwent ARR with allograft, xenografts, and stented bioprosthetic valved conduit from 2010 to 2020.
Surgical or Transcatheter Mitral Valve Replacement After Prior Bioprosthesis or Ring Implantation: A Landmark Analysis of Early and Long-Term Outcomes.
J Clin Med
November 2024
Department of Cardiac Surgery, Klinikum Nürnberg-Paracelsus Medical University, Breslauer Strasse 201, 90471 Nuremberg, Germany.
In recent years, the use of transcatheter valve-in-valve implantation in the mitral position (TMVI) for the treatment of mitral valve pathology following ring or bioprosthetic implantation has emerged as a less invasive option in comparison to repeated mitral valve surgery (RMVS). We aimed to compare the early and mid-term results of these two strategies. We retrospectively analyzed all patients who underwent a mitral intervention in our institution between 2005 and 2022.
View Article and Find Full Text PDFThree-dimensional transesophageal echocardiographic guided transcatheter puncture of the interatrial septum for mitral valve-in-valve replacement for mitral bioprosthetic valve failure.
Acta Cardiol
December 2024
Department of Ultrasound, Wuhan Asia Heart Hospital Affiliated to Wuhan University of Science and Technology, Wuhan Clinical Medical Research Center of Cardiovascular Imaging, Wuhan, China.
Yearly Trends and In-Hospital Outcomes of Patients Undergoing Transcatheter Mitral Valve-In-Valve Replacement in Prosthetic Valve Dysfunction.
Catheter Cardiovasc Interv
January 2025
Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA.
Introduction: Transcatheter mitral valve-in-valve replacement (TMVR ViV) is becoming a favorable, less invasive procedure among high-risk patients to manage mitral valve dysfunction. We aimed to investigate the trends of the predictors and outcomes of the procedure.
Methods: The national inpatient sample databases of 2016-2020 were analyzed using STATA 17 software and ICD-10 codes for TMVR ViV, with stratification for mitral stenosis (MS) or Mitral regurgitation (MR) as etiology for prosthetic valve dysfunction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!